Numeta G13%E Preterm, emulsion for infusion.
*Company:
Baxter Holding B.V.Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
Alanine Arginine Aspartic Acid Calcium Chloride Dihydrate Cysteine Glucose Monohydrate Glutamic acid Glycine Histidine Isoleucine Leucine Lysine Magnesium Acetate Tetrahydrate Methionine Ornithine Phenylalanine Potassium Acetate Proline Refined Olive Oil Refined Soybean Oil Serine Sodium Glycerophosphate, hydrated Taurine Threonine Tryptophan Tyrosine Valine *Additional information is available within the SPC or upon request to the company
Updated on 17 October 2024
File name
BE3004165_LABEL.pdf
Reasons for updating
- Change to section 3 - dose and frequency
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Change to warnings or special precautions for use
Updated on 31 July 2024
File name
ie-spc_Numeta G13E_PA2299-030-003_July 2024.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 09 August 2023
File name
Numeta Preterm G13E_labelling_UK IE.pdf
Reasons for updating
- New PIL for new product
Updated on 26 January 2023
File name
ie-spc-2021-02-numetag13-PA2299030003-clean.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 02 March 2021
File name
ie-spc-2021-02-numetag13-PA2299030003-clean.pdf
Reasons for updating
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 December 2020
File name
ie-spc-2020-09-numetag13-PA2299030003-clean.pdf
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 6.1 - List of excipients
- Change to section 6.2 - Incompatibilities
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 04 April 2019
File name
ie-spc-2019-03-numetag13-PA2299030003.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 October 2016
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)